| NAME |
SATRALIZUMAB-MWGE 120MG/ML INJ,SYRINGE,1ML |
| VA GENERIC NAME |
SATRALIZUMAB-MWGE |
| DOSAGE FORM |
INJ,SOLN |
| FDA MED GUIDE |
Satralizumab-mwge_(Enspryng)_(2022).pdf |
| HAZARDOUS TO DISPOSE |
NO |
| ACTIVE INGREDIENTS |
|
| CS FEDERAL SCHEDULE |
Unscheduled |
| STRENGTH |
120 |
| SINGLE/MULTI SOURCE PRODUCT |
Single source |
| UNITS |
MG/ML |
| NATIONAL FORMULARY NAME |
SATRALIZUMAB-MWGE INJ,SOLN |
| CREATE DEFAULT POSSIBLE DOSAGE |
YES |
| CODING SYSTEM |
|
| COPAY TIER |
-
- COPAY TIER LEVEL: 3
- COPAY EFFECTIVE DATE: 2020-08-27 00:00:00
|
| PGX ELIGIBLE |
NO |
| PGX SUPPRESSED |
NO |
| VA PRINT NAME |
SATRALIZUMAB-MWGE 120MG/ML INJ SYR 1ML |
| VA PRODUCT IDENTIFIER |
S0906 |
| TRANSMIT TO CMOP |
NO |
| VA DISPENSE UNIT |
SYR |
| MASTER ENTRY FOR VUID |
YES |
| VUID |
4039653 |
| EFFECTIVE DATE/TIME |
-
- 2020-08-27 00:00:00
- STATUS: ACTIVE
-
- 2020-08-27 00:00:00
- STATUS: ACTIVE
-
- 2020-08-27 00:00:00
- STATUS: ACTIVE
|